BrightPath Biotherapeutics

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, focused on developing innovative cancer immunotherapies. The company is advancing multiple product candidates, including ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for prostate cancer, and GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. Additionally, BrightPath is researching GRN-1301, aimed at targeting drug-resistant tumors, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Originally founded in 2003 as GreenPeptide Co., Ltd., the company rebranded in July 2017 to reflect its commitment to developing targeted treatments that stimulate immune responses against tumor-associated antigens.